An observational study in Colorectal Cancer, sponsored by Helse Stavanger HF. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Helse Stavanger HF · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Colorectal Neoplasms with a site in Norway — 19 open to participants now, 35 under way, 6 of them phase 3. Colorectal Neoplasms · Norway.
Among the 82 studies in Colorectal Neoplasms with a site in Norway, this one is the 4th largest by planned enrollment of the 12 observational ones that give a count, is one of 2 that started in 2013, is one of 12 observational ones, reaches primary completion later than 31 of the 34 other live ones, and was the 31st registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →19 of the 82 studies in Colorectal Neoplasms with a site in Norway are open now. Recruiting first, the newest first:
University of Edinburgh · Sites in Norway, United Kingdom
Ages 18+
Incyte Corporation · Sites in Norway, United States, Argentina and 19 more countries
Ages 18+
Sorlandet Hospital HF · Sites in Norway
Ages 40–75
Oncosyne AS · Sites in Norway
Ages 18+
GlaxoSmithKline · Sites in Norway, United States, Australia and 16 more countries
Ages 18+
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 22 · Phase 3 19
First in 1983; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,200 is above the median of 250 across 1,444 observational studies indexed under Colorectal Neoplasms.
Median enrollment 172 across the 68 interventional studies, 427 across the 12 observational. Of the 39 that completed or were terminated, 12 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 82 have an industry lead sponsor. The 10 most frequent:
Helse Stavanger HF is the lead sponsor of 97 studies on the registry; 18 are open to participants now.
Helse Stavanger HF has 2 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
5 of the studies in Colorectal Neoplasms with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04726800Anna MartlingCirculating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study | 2026-12 |
| NCT06333392Vestre Viken Hospital TrustTotal Underwater Colonoscopy (TUC) for Improved Colorectal Cancer Screening: A Randomized Controlled Trial | 2026-12 |
| NCT07255066University of EdinburghOptimizing Patient Treatment With EPA-enriched Nutrition, a Randomised Control Trial | 2027-01 |
| NCT03494946Oslo University HospitalLiver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer | 2027-01 |
| NCT05838768Novartis PharmaceuticalsStudy of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 82 studies in Colorectal Neoplasms with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective project in collecting and assessing clinical outcomes data related to molecular profiling of tumors based on cancer primary or metastatic tissue or tissue from peripheral blood samples. As a future part of the project will be collected patient reported outcomes (PROs) for assessing clinical outcomes in relation to clinical pathways, patient reported results, as well as tumor profiling by molecular methods.
All patients with colorectal cancer (primary and/or secondary) undergoing surgery for curative intent
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with primary and or metastatic colorectal cancer (CRC) eligible for curative surgery will be included. Subcohorts may be based on either colon cancer, rectal cancer, metastatic cancer, surgery (laparoscopy or open), node negative and node positive disease, and molecular profiling.
Procedure: open and laparoscopic surgery
Curative surgery for either primary (colorectal cancer, crc) or metastatic CRC (liver surgery)
Also known as: Liver surgery
Cancer-specific survival
Time from surgery to death of cancer
Time frame: 5-years
Recurrence-free survival
Time from surgery to recurrence of cancer
Time frame: 3 and 5 years
Plan to share: Undecided — Raw data may be provided given appropriate consent and approval for anonymous database sharing
Started Jan 2013 (actual). Primary completion is estimated for Dec 2035, 275 months after the start.
Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 275 months is above that.
Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Helse Stavanger HF